Skip to main content
Contact Us
Subscribe
E-Edition
70°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
201.44
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
47
48
Next >
$1000 Invested In Biogen 20 Years Ago Would Be Worth This Much Today
October 18, 2023
Via
Benzinga
3 Struggling Stocks Investors Shouldn't Buy on the Dip
October 18, 2023
These stocks have been brutal investments to own in recent years -- and investors shouldn't expect things to get better.
Via
The Motley Fool
Inquiry Into Biogen's Competitor Dynamics In Biotechnology Industry
October 16, 2023
Via
Benzinga
BIIB Stock Price Analysis: To Bet Or To Fold The Cards
October 14, 2023
Massachusetts-based Biogen (BIIB) is a global biotechnology leader, researching and developing therapies for debilitating diseases impacting the central nervous system.
Via
Talk Markets
Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage
October 13, 2023
The U.S.
Via
Benzinga
7 Low-Volatility Stocks to Buy if You’re a Concerned Investor
October 11, 2023
With market and economic conditions worrying many investors, it may be time to consider the virtues of low-volatility stocks.
Via
InvestorPlace
Analyst Ratings for Biogen
October 11, 2023
Via
Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,800 Today
October 03, 2023
Via
Benzinga
Is Biogen Stock a Buy Now?
September 28, 2023
It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.
Via
The Motley Fool
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
October 11, 2023
Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are...
Via
Benzinga
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
October 10, 2023
Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisai Co Ltd (OTC: ESALY)/ Biogen Inc's (NASDAQ:
Via
Benzinga
Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio
October 07, 2023
Jiangsu QYuns Therapeutics filed for a Hong Kong IPO to underwrite development of its portfolio of clinical stage biologic antibody drugs for autoimmune and allergic diseases. Meanwhile, Biogen...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Biotech Sector: On The Verge Of Triumph Or Turmoil?
October 06, 2023
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.
Via
Talk Markets
An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8
October 05, 2023
Paying Attention To Gold Miners On Zero Hedge on Monday, contributing editor “Quoth The Raven” suggested “paying urgent attention to gold miners”:
Via
Benzinga
(BIIB) - Analyzing Biogen's Short Interest
September 20, 2023
Via
Benzinga
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
September 15, 2023
Via
Benzinga
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
September 29, 2023
From
Biogen Inc.
Via
GlobeNewswire
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder
September 26, 2023
IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.
Via
Investor's Business Daily
Biogen Completes Acquisition of Reata Pharmaceuticals
September 26, 2023
From
Biogen Inc.
Via
GlobeNewswire
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
September 25, 2023
Benzinga
Via
Benzinga
Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
September 25, 2023
Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) and Biogen Inc (NASDAQ: BIIB) announced that humanized anti-soluble aggregated amyloid-beta (A&be
Via
Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
September 25, 2023
From
Biogen Inc.
Via
GlobeNewswire
California Attorney General Cracks Down On Deceptive Abortion Pill Reversal Claims
September 22, 2023
California Attorney General Rob Bonta has taken legal action against two anti-abortion organizations, Heartbeat International (HBI) and RealOptions Obria, for making unsupported claims about reversing...
Via
Benzinga
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
September 09, 2023
Buying a biotech is a good move, but it might not be enough to entice investors.
Via
The Motley Fool
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
September 07, 2023
Finding the best pharma stocks to buy takes a little effort, but it will pay of with these seven long-term winners.
Via
InvestorPlace
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
September 06, 2023
B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a
Via
Benzinga
3 Healthcare Stocks to Sell in September Before They Crash & Burn
September 06, 2023
The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse.
Via
InvestorPlace
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
September 06, 2023
Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.